Alert
Azithromycin in the newborn period increases the risk of developing pyloric stenosis.\textsuperscript{14-15}

| Indication | 1. Pertussis – post-exposure prophylaxis and treatment  
2. Neonatal chlamydial conjunctivitis and pneumonia  
3. Chlamydial and \textit{Mycoplasma} pneumonia >3 months of age  
4. Eradication of \textit{Ureaplasma} in preterm infants  
5. Prevention of BPD in preterm neonates – routine use is not recommended. |

| Action | Azithromycin inhibits protein synthesis by attaching to the 50S subunit of the bacterial ribosome in susceptible organisms. It exhibits bacteriostatic activity with higher potency than erythromycin against \textit{Ureaplasma} isolates in vitro. Azithromycin inhibits neutrophil influx and chemoattractant/cytokine release in murine lung non-infectious, as well as pneumonia, injury models. It is preferentially concentrated in pulmonary epithelial lining fluid and alveolar macrophages.\textsuperscript{14} |

| Drug Type | Macrolide antibiotic (subclass Azalide) |
| Trade Name | Azith, Azithromycin Alphapharm, Azithromycin DBL, Zithromax |
| Presentation | Oral: 200 mg/5 mL (15 mL) suspension, 500 mg tablet  
IV: 500 mg vial |

| Dosage/Interval | Pertussis (post-exposure prophylaxis or treatment)  
10 mg/kg/dose daily orally or IV\textsuperscript{2} for 5 days.  
Treatment of neonatal chlamydial conjunctivitis and pneumonitis  
20 mg/kg/dose daily orally for 3 days.  
Eradication of \textit{Ureaplasma} in preterm infants  
20 mg/kg/dose daily IV for 3 days.  
Pneumonia due to \textit{Chlamydia} or \textit{Mycoplasma pneumoniae} >3 months of age  
Initial therapy or therapy for serious infection: 10 mg/kg/dose IV once a day on days 1 and 2, followed by oral therapy if needed.  
Step-down or Mild therapy: 10 mg/kg ORALLY on day 1, followed by 5 mg/kg once daily on days 2–5. |

| Route | Oral  
IV |

| Maximum Daily Dose | 20 mg/kg |

| Preparation/Dilution | Oral: Add 9 mL of sterile water. Cap and shake well to produce 15 mL of suspension. Suspension expires 10 days after reconstitution. Write expiry date on bottle.  
IV: Add 4.8 mL of water for injection to the vial to make a concentration of 100 mg/mL solution. Shake until dissolved.  
Add 1 mL of reconstituted solution to 49 mL of sodium chloride 0.9% to make a concentration of 2 mg/mL and infuse over 1–3 hours.  
Maximum concentration for infusion is 2 mg/mL. |

| Administration | Oral: Shake well before use. May be given with or without feed.  
IV: Infuse over at least 1 hour. |

| Monitoring | During infusion – heart rate and blood pressure.  
IV site for signs of phlebitis.  
Liver function. |

| Contraindications | Hepatic dysfunction with prior azithromycin therapy.  
Concomitant therapy with QT interval prolonging drugs (e.g. cisapride) |

| Precautions | Hepatic dysfunction.  
IV solutions of a concentration greater than 2 mg/mL may cause local infusion-site reactions. |

| Drug Interactions | Drugs that can prolong QT interval.  
Digoxin – may result in digoxin toxicity. |
### Adverse Reactions
Common: Nausea, vomiting, abdominal pain and diarrhoea (all less than erythromycin).
Rare: Hypertrophic pyloric stenosis, thrombophlebitis (after IV administration), ventricular dysrhythmias (after IV administration). In general, the risk of dysrhythmias is increased when these agents are administered in combination with other drugs that prolong the QT interval. Increased liver enzymes, hepatitis, hepatic necrosis, hypersensitivity reactions.

### Compatibility
Fluids: Glucose 5%, glucose 5% in sodium chloride solutions, Hartmann’s, sodium chloride 0.9%, sodium chloride 0.45%
Y-site: Bivalirudin, ceftaroline fosamil, dexmedetomidine, tigecycline

### Incompatibility
Fluids: No information
Drugs: Amikacin, amiodarone, aztreonam, cefotaxime, ceftazidime, ceftriaxone, chlorpromazine, ciprofloxacin, clindamycin, fentanyl, furosemide (frusemide), gentamicin, imipenem-cilastatin, ketorolac, midazolam, morphine sulfate, mycophenolate mofetil, pentamidine, piperacillin-tazobactam (EDTA-free), potassium chloride, thiopental sodium, ticarcillin-clavulanate, tobramycin.

### Stability
Oral suspension: After reconstitution, the suspension should be stored below 30 °C and any remaining suspension discarded after 10 days.
Reconstituted IV solution: Stable for 24 hours at ≤30 °C.

### Storage
Oral/IV store below 25 °C. Protect from light.

### Special Comments
**Evidence summary**
Refer to full version.

### References
Refer to full version.

---

<table>
<thead>
<tr>
<th>Author: Neonatal Medicines Formulary Group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Original version Date:</strong> 20/06/2018</td>
</tr>
<tr>
<td><strong>Current Version number:</strong> 1.0</td>
</tr>
<tr>
<td><strong>Version Date:</strong> 20/06/2018</td>
</tr>
<tr>
<td><strong>Risk Rating:</strong> Medium</td>
</tr>
<tr>
<td><strong>Due for Review:</strong> 20/06/2021</td>
</tr>
<tr>
<td><strong>Approval by:</strong> JHCH CQ&amp;PCC</td>
</tr>
<tr>
<td><strong>Approval Date:</strong> 24/07/2018</td>
</tr>
</tbody>
</table>

**Authors Contribution**

Original author/s: Chris Wake, Srinivas Bolisetty
Revision author/s:
Expert review: Tony Lai, Brendan McMullan
Evidence Review: David Osborn
Nursing Review: Eszter Jozsa, Robyn Richards
Pharmacy Review: Jing Xiao, Carmen Burman, Cindy Chen
NMF Group contributors: Nilkant Phad, Himanshu Popat, Michael Hewson, Jessica Ryan, Joanne Patel, Roland Broadbent

Final content and editing review of the original: Ian Whyte
Electronic version: Cindy Chen, Ian Callander
Facilitator: Srinivas Bolisetty